肿瘤模型ICOS agonism by JTX-2011 (vopratelimab) requires initial T cell priming and Fc cross-linking for optimal T cell activation and anti-tumor immunity in preclinical models.
期刊:PloS one发表年份:2020作者:Amanda Hanson; Kutlu Elpek; Ellen Duong; Lindsey Shallberg; Martin Fan; Calvin Johnson; Matthew Wallace; George R Mabry; Stephen Sazinsky; Lauren Pepper; Chengyi J Shu; Sriram Sathyanarayanan; Sarah Zuerndorfer; Tyler Simpson; Monica Gostissa; Michae
